Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2010
03/11/2010CA2733709A1 5-substituted benzoxazines
03/10/2010EP2161282A1 Peptide analogues of PACAP
03/10/2010EP2161266A1 Benzofuran derivatives as orexin receptor antagonists
03/10/2010EP2161265A2 Compounds having selective inhibiting effect at GSK3
03/10/2010EP2161262A1 THCV and THCV extracts derived from plant material
03/10/2010EP2161252A1 N-Alkylcarbonyl-amino acid ester and N-Alkylcarbonyl-amino lactone compounds and their use
03/10/2010EP2161026A1 Combination of extracts from various plants to improve the symptoms of mental illnesses
03/10/2010EP2160470A2 Chimeric pufa polyketide synthase systems and uses thereof
03/10/2010EP2160390A1 Novel process
03/10/2010EP2160387A2 Heteroarylamide pyrimidone compounds
03/10/2010EP2160380A1 Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
03/10/2010EP2160196A2 Compounds for the treatment of ischemia and neurodegeneration
03/10/2010EP2160195A1 Novel muscle relaxant using negative charge gold nanoparticle with choline
03/10/2010EP2160183A1 Extended release formulations comprising quetipine and methods for their manufacture
03/10/2010EP2027122B1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
03/10/2010EP2013166B1 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
03/10/2010EP1863818B1 Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
03/10/2010EP1841423B1 Use of 1- benzyl-1- hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides and related compounds as analgesics
03/10/2010EP1828182B1 Therapeutic pyrazolo[3,4-b]pyridines and indazoles
03/10/2010EP1765816B1 Substituted 1-propiolylpiperazines having an affinity for the mglur5 receptor in order to treat painful conditions
03/10/2010EP1745031B1 Crystalline forms of duloxetine free base
03/10/2010EP1677833B1 Virus vector for use in in vivo gene therapy of Parkinson's disease
03/10/2010EP1605964B1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
03/10/2010EP1483588B1 Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
03/10/2010EP1313699B1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
03/10/2010CN101668560A Acetylene derivatives and their use for binding and imaging amyloid plaques
03/10/2010CN101665536A Anti-vegf antibodies
03/10/2010CN101665469A Heterocyclic compounds useful as Nurrl activators
03/10/2010CN101664388A transnasal transport/immunisation with highly adaptable carriers
03/09/2010US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
03/09/2010US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants
03/09/2010US7674604 Using computer modeling to identify positions where cysteinal insertion will lock protein comprising integrin domain sequences into preferential configuration; directed protein evolution
03/09/2010US7674463 Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
03/09/2010US7674455 treating a mammal having amyotrophic lateral sclerosis by transducing a motor neuron of the mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; neurodegenerative disorders
03/09/2010US7674453 Tumor necrosis factor combined with interferon in demyelinating diseases
03/09/2010CA2537598C Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
03/09/2010CA2431952C Muscarinic antagonists
03/09/2010CA2411922C Composition for pain mediation and apparatus and method of use thereof
03/09/2010CA2407972C Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists
03/09/2010CA2399813C Indol-3-yl derivatives
03/09/2010CA2389476C Treatment of dyskinesia with a h3-histamine receptor agonist
03/09/2010CA2388395C Compound
03/09/2010CA2382464C High-affinity choline transporter
03/09/2010CA2379282C Amido spiropiperidines promote the release of growth hormone
03/09/2010CA2336702C Sulfonylaminocarboxylic acid n-arylamides as guanylate cyclase activators
03/09/2010CA2228847C Ibogamine congeners
03/04/2010WO2010025322A2 Magnetic nanodelivery of therapeutic agents across the blood brain barrier
03/04/2010WO2010025251A2 Materials and methods for modulating appetite, weight gain and adhd using varenicline
03/04/2010WO2010025235A1 Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
03/04/2010WO2010024980A1 4'-amino cyclic compounds having 5-ht6 receptor affinity
03/04/2010WO2010024927A2 Treatment of amyloidoses using myelin basic protein and fragments thereof
03/04/2010WO2010024911A1 Methods for increasing neurogenesis
03/04/2010WO2010024908A1 Methods for treatment of multiple sclerosis
03/04/2010WO2010024769A1 New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits
03/04/2010WO2010024717A1 Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment
03/04/2010WO2010024432A1 Therapeutic agent for central nervous system injury
03/04/2010WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity
03/04/2010WO2010024110A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative
03/04/2010WO2010023512A1 Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
03/04/2010WO2010023197A2 Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/04/2010WO2010023170A1 Dosage form comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine or a salt thereof
03/04/2010WO2010022568A1 A medication for use in abstinence of drugs and preparation thereof
03/04/2010WO2010005581A4 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
03/04/2010WO2010004215A3 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
03/04/2010WO2009156951A3 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
03/04/2010WO2009156860A3 4-(pyridin-4-yl)-1h-(1, 3, 5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
03/04/2010WO2009134877A3 Therapeutics for treatment resistant mental disorders
03/04/2010WO2009120810A3 Neurodegenerative disorders
03/04/2010WO2009087005A4 Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain
03/04/2010US20100058488 Protein formulations comprising s1-5
03/04/2010US20100056636 N-Substituted-P-Menthane-3-Carboxamide and Uses Thereof
03/04/2010US20100056632 CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
03/04/2010US20100056622 Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases
03/04/2010US20100056617 Role of limonoid compounds as neuroprotective agents
03/04/2010US20100056613 Spiroquinone compound and pharmaceutical composition
03/04/2010US20100056604 Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
03/04/2010US20100056595 Pyrazole Derivatives as P2X7 Modulators
03/04/2010US20100056591 Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
03/04/2010US20100056584 Novel 2-aminio-pyridine derivatives and their use as potassium channel modulators
03/04/2010US20100056574 Crystalline Forms of Sufentanil
03/04/2010US20100056573 2-alkyl-indazole compounds for the treatment of certain cns-related disorders
03/04/2010US20100056561 Hydrochloride salt of an azabicyclo[3.2.1]octane derivative
03/04/2010US20100056553 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
03/04/2010US20100056545 Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of t-type calcium ion channel containing the same as an active ingredient
03/04/2010US20100056538 Pro-drugs of A2B Adenosine Receptor Antagonists
03/04/2010US20100056531 Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
03/04/2010US20100056527 Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
03/04/2010US20100056520 Formulations of phospholipase enzyme inhibitors
03/04/2010US20100056518 Cycloalkylamine substituted isoquinolone derivatives
03/04/2010US20100056515 Benzimidazole compounds
03/04/2010US20100056504 Novel 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester- introduced phenyl group as substituents
03/04/2010US20100056501 Substituted lactams as inhibitors of abeta protein production
03/04/2010US20100056499 3-amino-1-arylpropyl azaindoles and uses thereof
03/04/2010US20100056498 Substituted monocyclic cgrp receptor antagonists
03/04/2010US20100056495 Dimeric iap inhibitors
03/04/2010US20100056491 4'-amino cyclic compounds having 5-ht6 receptor affinity
03/04/2010US20100056490 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors
03/04/2010US20100056489 Treatment of neuropathic pain
03/04/2010US20100056487 Modulators of amyloid-beta production
03/04/2010US20100056484 Dietary supplemental composition effective for enhancing cognitive performance, elevating mood and reducing oxidative stress
1 ... 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 ... 1833